WO2006080192A1 - 癌に特異的な遺伝子及びそれを用いた診断キット - Google Patents
癌に特異的な遺伝子及びそれを用いた診断キット Download PDFInfo
- Publication number
- WO2006080192A1 WO2006080192A1 PCT/JP2006/300242 JP2006300242W WO2006080192A1 WO 2006080192 A1 WO2006080192 A1 WO 2006080192A1 JP 2006300242 W JP2006300242 W JP 2006300242W WO 2006080192 A1 WO2006080192 A1 WO 2006080192A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- seq
- polynucleotide
- primer
- nucleotide sequence
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to a gene specific for cancer and a diagnostic kit using the same, and further relates to a method using the same.
- Early detection of carcinoma is the most important issue as a countermeasure against cancer.
- early detection is more important because cancer that has developed in the upper part of the large intestine has few subjective symptoms and has a high risk of progression.
- screening for colorectal cancer has been mainly performed by screening of fecal occult blood, diagnosis using serum markers such as CEA or CA19-9-9, and diagnosis of the course of treatment.
- serum markers such as CEA or CA19-9-9
- a molecular biological diagnostic method using a cancer tissue-specific protein marker has been proposed as a method that enables simple and reliable early diagnosis of malignant tumors. Since this method does not require large-scale equipment and places little burden on the subject, it can be widely applied to many subjects who have no subjective symptoms.
- Japanese Patent Application Laid-Open No. 7-5 10 65 discloses the use of glycoprotein 39 as a tumor marker.
- International Publication No. 2 0 4Z0 1 8 6 7 9 pamphlet describes a technique relating to a cancer diagnostic kit using C EN P.-A.
- Patent Document 1 alone still has a problem about completely confirming the onset of cancer, and it is necessary to make a more reliable determination by using a plurality of means.
- an object of the present invention is to provide further identification of a gene related to the expression of a new cancer and a diagnostic kit using the gene. Disclosure of the invention
- the present invention employs the following specific means.
- the polynucleotide described in any one of the following (a) to (c) is used.
- C a polynucleotide comprising a nucleotide sequence having at least 70% homology with a complementary nucleotide sequence to 5; (c) one or several amino acids in the amino acid sequence of SEQ ID NO: 2 or its amino acid sequence A polynucleotide encoding a protein comprising an amino acid sequence in which is deleted, substituted or added.
- D is also preferred. Since it was confirmed that the polynucleotide in this means was highly expressed in the tissue of the cancerous part, it can greatly contribute to cancer diagnosis by using it as a marker.
- the homology with the nucleotide sequence set forth in SEQ ID NO: 1 Therefore, it is preferably 0% or more, more preferably 80%, and even more preferably 90% or more.
- the second means is a nucleic acid molecule containing the polynucleotide in the first means.
- the third means is a cancer diagnostic kit using the polynucleotide and the specific factor in the first means.
- the term “specific gene” means that the affinity for a polynucleotide is more significant than the affinity for other unrelated (especially those with less than 30% identity) polynucleotides. It is expensive.
- the affinity can be measured by, for example, hybridization assay or binding assay.
- the specific factor is at least one of the group consisting of nucleic acid molecules, polypeptides, lipids, sugar chains, small organic molecules, and complex molecules thereof, and the cancer diagnostic kit diagnoses
- the cancer to be detected is preferably rectal cancer or colon cancer.
- a primer having the base sequence set forth in SEQ ID NO: 3 is used.
- a primer having the base sequence set forth in SEQ ID NO: 4 is used.
- a primer set comprising the primer set forth in SEQ ID NO: 3 and the primer set forth in SEQ ID NO: 4 is used.
- a seventh means a step of determining the expression level of the protein comprising the amino acid sequence described in SEQ ID NO: 2 for each of the two collected cells, Calculating the ratio of the expression levels.
- the ratio of the expression level differs between the two It can be determined that the person is a high-risk person suspected of having cancer.
- the step of determining the protein expression level is to use a western plot, that one of the two collected cells is a cell in a non-cancerous tissue, and that the two collected cells are It is also desirable that one of them is a cell in a cancerous tissue and a step of determining whether or not the ratio of the calculated expression levels is 1.7 or more.
- a gene associated with cancer expression can be further specified, and a diagnostic kit using the gene can be provided.
- FIG. 1 shows the results of Western plotting for C EN P-H.
- FIG. 2 is a diagram showing the results of Western blotting for hM i s 12.
- FIG. 3 is a diagram showing the results of staining a cross section of a rectal cancer tissue and a non-rectal cancer tissue adjacent thereto with an anti-human CENP—H polyclonal antibody.
- Figure 4 shows the results of investigating the amount of C EN P-H mRNA on each surface of rectal cancer tissue and normal tissue using RT-PCR and real-time quantitative PCR.
- Fig. 5 shows the results of investigating the amount of C EN P—H mRNA on each surface of rectal cancer tissue and normal tissue using RT-PCR and real-time quantitative PCR.
- Tissues from 5 bodies were collected by surgical methods. Tissues were collected from cancerous tissues (hereinafter referred to as “cancerous tissues”) and tissues located 5 to 10 cm away from the cancerous tissues (hereinafter referred to as “non-cancerous tissues”). The collected tissue was immediately immersed in liquid nitrogen and stored frozen at 180 ° C.
- cryopreserved tissue was added to lysis buffer (7 M urea, 2 M thiourea, 2% 3— [(3—Cho 1 amidopropy 1) D imethy 1 a mm onio] — 1— P ropanesu 1 fonate, 0. 1 MD TT, 2% IPG buffer (Amersha mP harmacia Biotech), 40 mM Tris) A, po 1 ytronhomogenizer (Kinematica) was used to dissolve, Centrifuge 4. After 1 hour, the supernatant was collected and the protein was extracted.
- Protein is stored in a tank transfer device (Bio-Rad) It was transferred to olyvinylidenefluoride membranes (M i 1 1 ipore), and the membrane was first blocked with Phosphate Bufferedsaline (PBS) containing 5% skimmilk.
- PBS Phosphate Bufferedsaline
- a rabbit anti-CENP-H antibody diluted 1: 500 a rabbit anti-hM isl 2 antibody diluted 1: 100
- Anti- ⁇ -actin antibodies in B-locking buffer were used, and the secondary antibodies were: 1: 300 000 diluted rabbit anti-rabbit I g GHRP, 1: 5 000 diluted rabbit anti-rabbit
- the caps I g G HR P, each in b 1 ockingbuffer were used.
- the antibody on the antigen membrane was detected with an enhanced chemiluminescence detection reagent (Am er sham P ham a c aia Biotech). The intensity of each band was measured by NIH images.
- RNA was extracted from cancer tissue and non-cancer tissue using RN easy Mini Kit (manufactured by Qiagen). CDNA was synthesized from each of the extracted total RNAs using 1 st trandc DNA synthesis kit for RT-PCR (Roche).
- each cDNA obtained by this synthesis was used as a template, and the cDNA of CEMP-H was amplified by PCR.
- a primer having the base sequence shown in SEQ ID NO: 3 is used as a forward primer having a base sequence shown in SEQ ID NO: 4 as a reverse, and GAP DH is used as a control.
- CDNA or actin was amplified.
- C EN P—H cDNA real-time quantitative PCR was performed in the Light Cyc 1er library.
- the PCR reaction mixture used was Light Cycler DNA Master SYBRG reen I (Fast Start Taq DNA Polymerase, dNTP, Buffer 1, SYBRG reen I), and 3 MgCl 2 was added to it.
- O mM, the primer set forth in SEQ ID NO: 3 and the primer set forth in SEQ ID NO: 4 were added in an amount of 0.5 ⁇ 0 each, and the reaction was performed in a total of 2. ⁇ 2 ..
- Frozen tissue sections were dried in slide glass and fixed in 4 ° C acetone. After washing 3 times with P B S, the cells were blocked with b 1 o c ki ng buf er (10% bovine fetal serum, P B S) for 1 hour.
- Samples were prepared using either one or both of rabbit anti-C EN P—H antibody diluted 1: 200, and anti-human CENP—A monoclonal antibody diluted 1: 100, 3% bovine Serum in albumin / PBS for 1 hour. After washing with PBS, the sample was diluted 1: 100 A 1 e X a Fluor TM 4 8 8 or 5 9 4 conjugated goat anti-rabbit anti-mouse Ig G secondary anti- ⁇ : (M o 1 ocu 1 ar Probes) and / or A 1 exa Fluor TM 5 94 4-conjugated goat anti-mouse Ig G secondary antibody and incubated for 1 hour. .
- DNA is DA PIIIIC ounterstain (Vysis) Was counterstained. The sample was observed with a fluorescence microscope (Leica QFISH). For HE staining, tissue sections were stained with hematoxy 1 in for 30 minutes, dried with 100% ethanol and xylene, and sealed with P ermount.
- FIG. 1 shows the results of the Western plot.
- C EN P 1 H was very much expressed in cancer tissues in all 15 cases.
- the ratio of C EN P—H expression between non-cancerous tissue and cancerous tissue was 1.7 to 9.6, and there was a large difference between cancerous tissue and non-cancerous tissue.
- hM isl 2, which is another centromere protein
- no particular difference was found in cancerous tissue and non-cancerous tissue (see Fig. 2, Case in the figure).
- the number indicates the same organization as the Case number in Figure 1).
- FIG. 3 shows the HE-stained image of the cancerous part
- Figures 3 (b), (c) and (d) show the immunostained images of the cancerous part with CENP-H antibody
- Figure 3 (e) shows the non-cancerous part
- Fig. 3 (f) shows the CENP-H stained image of the non-cancerous part.
- CENP-H like other centromeric proteins like C EN P-A and C EN P-C, appears in small spots in the cell nucleus, consistent with the centromere. It was confirmed to exist as a point. Its C EN P—H increases in number and size in cancerous areas compared to non-cancerous tissues (Fig. 3 (f)). (See Fig. 3 (c) and (d)). Stained C EN P—H was confirmed not in the stromal cells but in the cancerous epithelium. This experiment was performed on various tissue sections, and all showed similar results.
- C EN P—H was expressed in cancer cell lines.
- C EN P—H mRNA levels in colorectal cancer tissues and C EN P in non-cancerous tissues —H The amount of mRNA was analyzed using RT-PCR and real-time quantitative PCR. The results are shown in FIGS.
- Fig. 5 compares the mRNA expression levels shown in Fig. 4 between non-cancerous and cancerous tissues, and was determined by the statistical analysis of the start view. According to Fig. 5, cancer tissue (Canc cer) was expressed about 5 times higher than non-cancerous tissue (Norm a 1). This also showed that the presence of cancer can be confirmed by examining the expression of C EN P—H. Industrial applicability
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06702529A EP1845156A4 (en) | 2005-01-05 | 2006-01-05 | SPECIFIC CANCER GENE AND DIAGNOSTIC KIT USING THE SAME |
JP2007500454A JP4677565B2 (ja) | 2005-01-05 | 2006-01-05 | 癌に特異的な遺伝子及びそれを用いた診断キット |
US11/794,798 US7998693B2 (en) | 2005-01-05 | 2006-01-05 | Gene specific to cancer and diagnosis kit using the same |
CN2006800013503A CN101090965B (zh) | 2005-01-05 | 2006-01-05 | 对癌特异的基因和采用该基因的诊断试剂盒 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-001033 | 2005-01-05 | ||
JP2005001033 | 2005-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006080192A1 true WO2006080192A1 (ja) | 2006-08-03 |
Family
ID=36740226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/300242 WO2006080192A1 (ja) | 2005-01-05 | 2006-01-05 | 癌に特異的な遺伝子及びそれを用いた診断キット |
Country Status (5)
Country | Link |
---|---|
US (1) | US7998693B2 (ja) |
EP (1) | EP1845156A4 (ja) |
JP (1) | JP4677565B2 (ja) |
CN (1) | CN101090965B (ja) |
WO (1) | WO2006080192A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0751065A (ja) | 1992-02-21 | 1995-02-28 | Nippon Koutai Kenkyusho:Kk | 糖タンパク質39遺伝子 |
WO2003104426A2 (en) | 2002-06-10 | 2003-12-18 | Merck & Co., Inc. | Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof |
WO2004018679A1 (ja) | 2002-08-23 | 2004-03-04 | Japan Science And Technology Agency | 癌診断のための方法およびキット |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002059260A2 (en) | 2000-11-17 | 2002-08-01 | Hyseq, Inc. | Nucleic acids and polypeptides |
-
2006
- 2006-01-05 WO PCT/JP2006/300242 patent/WO2006080192A1/ja active Application Filing
- 2006-01-05 US US11/794,798 patent/US7998693B2/en not_active Expired - Fee Related
- 2006-01-05 JP JP2007500454A patent/JP4677565B2/ja not_active Expired - Fee Related
- 2006-01-05 CN CN2006800013503A patent/CN101090965B/zh not_active Expired - Fee Related
- 2006-01-05 EP EP06702529A patent/EP1845156A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0751065A (ja) | 1992-02-21 | 1995-02-28 | Nippon Koutai Kenkyusho:Kk | 糖タンパク質39遺伝子 |
WO2003104426A2 (en) | 2002-06-10 | 2003-12-18 | Merck & Co., Inc. | Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof |
WO2004018679A1 (ja) | 2002-08-23 | 2004-03-04 | Japan Science And Technology Agency | 癌診断のための方法およびキット |
Non-Patent Citations (5)
Title |
---|
See also references of EP1845156A4 * |
SUGATA N. ET AL.: "Characterization of a novel kinetochore protein, CENP-H", J. BIOL. CHEM., vol. 247, no. 39, 1999, pages 27343 - 27346, XP003001280 * |
SUGATA N. ET AL.: "Human CENP-H multimers colocalize with CENP-A and CENP-C at active centromere-kinetochore complexes", HUM. MOL. GENET., vol. 9, no. 19, 2000, pages 2919 - 2926, XP003001279 * |
SUGATA, N. ET AL.: "Human CENP-H multimers colocalize with CENP-A and CENP-C at active centromere-kinetochore complexes", HUM. MOL. GENET., vol. 9, no. 19, 2000, pages 2919 - 2926 |
TOMONAGA T. ET AL.: "Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy", CANCER RES., vol. 65, no. 11, June 2005 (2005-06-01), pages 4683 - 4689, XP003001281 * |
Also Published As
Publication number | Publication date |
---|---|
CN101090965A (zh) | 2007-12-19 |
EP1845156A1 (en) | 2007-10-17 |
JP4677565B2 (ja) | 2011-04-27 |
US20100196928A1 (en) | 2010-08-05 |
US7998693B2 (en) | 2011-08-16 |
EP1845156A4 (en) | 2008-04-23 |
JPWO2006080192A1 (ja) | 2008-06-19 |
CN101090965B (zh) | 2012-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10024859B2 (en) | Markers for detection of gastric cancer | |
CN107326066B (zh) | 用于膀胱癌检测的尿标记物 | |
EP1272668B1 (en) | Methods, compositions and kits for the detection and monitoring of breast cancer | |
CN101410532B (zh) | 用于检测癌症的尿基因表达比值 | |
US20060286578A1 (en) | Detection of 5T4 RNA in plasma and serum | |
KR101007567B1 (ko) | 대장암 과발현 유전자를 이용한 대장암 진단 마커 | |
AU2017201343B2 (en) | Molecular biomarker set for early detection of ovarian cancer | |
KR101657051B1 (ko) | 만성폐쇄성폐질환 진단용 마커 조성물 | |
KR101289454B1 (ko) | 소세포폐암 및 비소세포폐암 진단 마커로서의 보체 c9 | |
KR101878974B1 (ko) | 신장암 진단용 조성물과 진단 마커 검출 방법 | |
EP1682679B1 (en) | Molecular marker | |
WO2006080192A1 (ja) | 癌に特異的な遺伝子及びそれを用いた診断キット | |
KR101054953B1 (ko) | 간암을 진단 및 치료하기 위한 분자인 snx14, 그를 포함하는 키트 | |
RU2537263C2 (ru) | Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты) | |
ES2319533T3 (es) | Diagnostico del riesgo de cancer de pecho. | |
KR101054951B1 (ko) | 간암을 진단 및 치료하기 위한 분자인 capn12, 그를 포함하는 키트 | |
KR101060192B1 (ko) | 대장암 과발현 유전자를 이용한 대장암 진단 마커 | |
KR101060193B1 (ko) | 대장암 과발현 유전자를 이용한 대장암 진단 마커 | |
KR20100086362A (ko) | 간암 진단 마커인 apoa1, 그를 포함하는 키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007500454 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680001350.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11794798 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2006702529 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006702529 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2006702529 Country of ref document: EP |